Targeting Innate Immunity in Glioma Therapy
International Journal of Molecular Sciences · 12.01.2024 · 25 (2) · 947
DOI: 10.3390/ijms25020947 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.01.2024. Verfasst von Andrew G Gillard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Glioblastoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, the National Cancer Institute (NCI) of the National Institutes of Health (NIH), The American League Auxiliary (ALA) Fellowship in Cancer Research Award.
Abstract (Originalsprache)
Currently, there is a lack of effective therapies for the majority of glioblastomas (GBMs), the most common and malignant primary brain tumor. While immunotherapies have shown promise in treating various types of cancers, they have had limited success in improving the overall survival of GBM patients. Therefore, advancing GBM treatment requires a deeper understanding of the molecular and cellular mechanisms that cause resistance to immunotherapy. Further insights into the innate immune response are crucial for developing more potent treatments for brain tumors. Our review provides a brief overview of innate immunity. In addition, we provide a discussion of current therapies aimed at boosting the innate immunity in gliomas. These approaches encompass strategies to activate Toll-like receptors, induce stress responses, enhance the innate immune response, leverage interferon type-I therapy, therapeutic antibodies, immune checkpoint antibodies, natural killer (NK) cells, and oncolytic virotherapy, and manipulate the microbiome. Both preclinical and clinical studies indicate that a better understanding of the mechanisms governing the innate immune response in GBM could enhance immunotherapy and reinforce the effects of chemotherapy and radiotherapy. Consequently, a more comprehensive understanding of the innate immune response against cancer should lead to better prognoses and increased overall survival for GBM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
ORCID-Profile: Andrew G Gillard, Dong Ho Shin, Candelaria Gomez-Manzano
Förderung
- NCI NIH HHS
- the National Cancer Institute (NCI) of the National Institutes of Health (NIH)
- The American League Auxiliary (ALA) Fellowship in Cancer Research Award
- The John and Rebekah Harper Fellowship
- Alliance for Cancer Gene Therapy
- Chance for Life
- Cure Starts Now
- the Partnership for Careers in Cancer Science and Medicine, Division of Education & Training, at MD Anderson Cancer Center
Zitieren
APA
Gillard, A. G., Shin, D. H., Hampton, L. A., Lopez-Rivas, A., Parthasarathy, A., Fueyo, J., & Gomez-Manzano, C. (2024). Targeting Innate Immunity in Glioma Therapy. International Journal of Molecular Sciences, 25(2), 947. https://doi.org/10.3390/ijms25020947
Vancouver
Gillard AG, Shin DH, Hampton LA, Lopez-Rivas A, Parthasarathy A, Fueyo J, et al. Targeting Innate Immunity in Glioma Therapy. International Journal of Molecular Sciences. 2024;25(2):947. doi:10.3390/ijms25020947
BibTeX
@article{Gillard2024,
author = {Gillard, Andrew G and Shin, Dong Ho and Hampton, Lethan A and Lopez-Rivas, Andres and Parthasarathy, Akhila and Fueyo, Juan and Gomez-Manzano, Candelaria},
title = {Targeting Innate Immunity in Glioma Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {2},
pages = {947},
doi = {10.3390/ijms25020947}
}
EUVIMED